Please ensure Javascript is enabled for purposes of website accessibility

What Happened in the Stock Market Today

By Jim Crumly - Aug 27, 2018 at 5:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As stocks surged on positive trade news, Tesla slipped after calling off plans to go private, and Pfizer released information that caused big movements in some biotech stocks.

Stocks powered higher on news of a trade agreement between the U.S. and Mexico. The Dow Jones Industrial Average (^DJI 0.60%) broke 26,000 for the first time since February, and the S&P 500 (^GSPC 0.95%) closed at a record high.

Today's stock market

Index Percentage Change Point Change
Dow 1.01% 259.29
S&P 500 0.77% 22.05

Data source: Yahoo! Finance.

Biotech stocks surged, with the iShares NASDAQ Biotechnology ETF (IBB 0.17%) rising 1.8%. The retail sector was weak; the SPDR S&P Retail ETF (XRT 6.88%) slipped 0.7%. 

As for individual stocks, Tesla (TSLA 4.88%) investors largely shrugged off the announcement that it will remain a public company, and Pfizer (PFE 0.56%) presented details of a drug trial that had big implications for smaller competitors.

Bull statue on Wall Street.

Image source: Getty Images.

Tesla's go-private plans are off

Shares of Tesla slipped 1.1% to $319.27 following founder and CEO Elon Musk's late-night announcement on Friday that plans to take the company private are being dropped. Musk said in a blog post that according to feedback he has received, most shareholders would prefer the company to stay public. Tesla's independent directors also released a statement saying that the special committee set up to pursue the transaction has been dissolved.

Seventeen days after unexpectedly tweeting that funding was secured and that "[i]nvestor support is confirmed" for a deal to take Tesla private at $420 a share, Musk admitted that there were significant roadblocks to his plan. Some institutional shareholders have limitations on how much they can invest in private companies, and there is "no proven path" for most retail investors to continue to own Tesla shares if it were private. The mercurial CEO also said that the process of going private would be time-consuming and a distraction at a critical point in the company's history. 

In other words, the reasons for canceling the deal are not very different from the questions observers have been raising since the original announcement, which had the stock price careening between $387 and $288. The muted reaction to the doomed idea today was probably more of a sigh of relief than anything.

Pfizer releases drug trial details

Drug giant Pfizer released details of a successful trial of a drug for heart damage from a rare disease, and although that company's stock had little reaction, falling 1.9%, shares of companies with potentially competing drugs reacted sharply. Alnylam Pharmaceuticals (ALNY -0.24%) soared 16.2%, Ionis Pharmaceuticals (IONS -0.67%) jumped 7.8%, and Eidos Therapeutics (EIDX) plunged 31.1%.

The trial was for tafamidis, a drug for transthyretin amyloid cardiomyopathy, a rare and fatal disease where destabilized amyloid proteins accumulate in the heart and cause damage. Tafamidis stabilizes the proteins, slowing the progression of the disease, and the test results showed that it reduces hospitalization by 32% and mortality by 30%.

TTR amyloidosis (ATTR), the disease that leads to the heart damage, comes in two forms: a hereditary form caused by a gene mutation, and an age-rated version called "wild type" ATTR. The Pfizer drug is meant to stabilize the disease in both forms, while the drugs from Ionis and Alnylam are based on a new approach designed to silence the production of the abnormal proteins at the source, and are aimed at addressing nerve damage caused by the hereditary form only. In today's presentation, Pfizer revealed that the test results that showed benefits for subjects with the hereditary form did not have statistical significance, suggesting that the immediate threat to Ionis and Alnylam may be smaller than investors had feared.

On the other hand, Eidos, a small biotech that had its initial public offering in June, is working on a drug that targets both types of ATTR with a stabilization approach, putting it in head-to-head competition with Pfizer. It's not all over for Eidos by any means, but Pfizer is further along, and that had investors worried about its stock today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.71 (0.56%) $0.30
Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$36.86 (-0.67%) $0.25
Tesla, Inc. Stock Quote
Tesla, Inc.
TSLA
$658.80 (4.88%) $30.64
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$126.75 (-0.24%) $0.30
Eidos Therapeutics, Inc. Stock Quote
Eidos Therapeutics, Inc.
EIDX
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$32,120.28 (0.60%) $191.66
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$3,978.73 (0.95%) $37.25
SPDR Series Trust - SPDR S&P Retail ETF Stock Quote
SPDR Series Trust - SPDR S&P Retail ETF
XRT
$63.24 (6.88%) $4.07
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$114.77 (0.17%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.